MWM
CPRX

Mission Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Mission Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Buy
11,202
+81
+0.7% +$2.39K ﹤0.01% 813
2026
Q1 		$275K Buy
11,121
+3
+0% +$71 0.01% 635
2025
Q4 		$259K Buy
11,118
+300
+3% +$6.68K 0.01% 638
2025
Q3 		$213K Buy
10,818
+198
+2% +$4.07K ﹤0.01% 669
2025
Q2 		$230K Buy
10,620
+510
+5% +$12K ﹤0.01% 630
2025
Q1 		$245K Buy
10,110
+10
+0.1% +$225 0.01% 596
2024
Q4 		$211K Buy
+10,100
New +$217K ﹤0.01% 622

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mission Wealth Management's CPRX Position: Q2 2026 in Review

Mission Wealth Management increased its Catalyst Pharmaceutical (CPRX) stake by 0.73% in Q2 2026, buying an estimated $2.39K and bringing the position to 11,202 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #813.

Mission Wealth Management first reported a position in CPRX in Q4 2024 and has held it in 7 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Mission Wealth Management held 11,202 shares of Catalyst Pharmaceutical worth $352K as of Q2 2026.
  • Mission Wealth Management bought 81 Catalyst Pharmaceutical shares in Q2 2026, an estimated $2.39K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Mission Wealth Management's portfolio in Q2 2026, its #813 holding.
  • Mission Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Mission Wealth Management's 13F filing for Q2 2026, filed 20 Jul 2026.